Hims & Hers Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Hims & Hers Health (HIMS).

Price Target Range — 10 Quarters

Analyst Consensus — 14 Analysts

3Buy

11Hold

Consensus RatingHold# Analysts14Avg. Consensus PT$31Upside to Avg. PT+7.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 11, 2026	JP Morgan	Cory Carpenter	Assumes	Neutral	$32
Aug 24, 2026	Truist Securities	Jailendra Singh	PT Raise	Hold	$27→$32
Aug 21, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$39→$35
Aug 11, 2026	Citigroup	Daniel Grosslight	PT Cut	Neutral	$35→$33
Aug 11, 2026	Deutsche Bank	George Hill	PT Raise	Hold	$25→$26
Aug 11, 2026	B of A Securities	Allen Lutz	PT Raise	Neutral	$30→$32
Aug 11, 2026	TD Cowen	Jonna Kim	PT Raise	Hold	$25→$30
Aug 11, 2026	Morgan Stanley	Craig Hettenbach	PT Raise	Equal-Weight	$21→$28
Aug 11, 2026	Needham	Ryan MacDonald	PT Raise	Buy	$35→$42
Jul 24, 2026	Truist Securities	Jailendra Singh	PT Raise	Hold	$23→$27
Jul 23, 2026	Citigroup	Daniel Grosslight	PT Raise	Neutral	$28→$35
Jul 9, 2026	B of A Securities	Allen Lutz	PT Raise	Neutral	$36→$37
Jul 1, 2026	Canaccord Genuity	Maria Ripps	PT Raise	Buy	$32→$40
Jul 1, 2026	B of A Securities	Allen Lutz	PT Raise	Neutral	$25→$36
Jun 18, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$29→$39
May 26, 2026	B of A Securities	Allen Lutz	PT Cut	Neutral	$28→$25
May 22, 2026	Truist Securities	Jailendra Singh	PT Raise	Hold	$18→$23
May 19, 2026	B of A Securities	Allen Lutz	PT Cut	Neutral	$30→$28
May 13, 2026	B of A Securities	Allen Lutz	PT Cut	Neutral	$32→$30
May 12, 2026	Citigroup	Daniel Grosslight	PT Raise	Neutral	$24→$28

Analyst Ratings News

PRO
Truist Securities Maintains Hold on Hims & Hers Health, Raises Price Target to $32

Truist Securities analyst Jailendra Singh maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $27 to $32.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Hims & Hers Health, Lowers Price Target to $35

Barclays analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Overweight and lowers the price target from $39 to $35.

Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Hims & Hers Health, Lowers Price Target to $33

Citigroup analyst Daniel Grosslight maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and lowers the price target from $35 to $33.

Benzinga Newsdesk

PRO
Deutsche Bank Maintains Hold on Hims & Hers Health, Raises Price Target to $26

Deutsche Bank analyst George Hill maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $25 to $26.

Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Hims & Hers Health, Raises Price Target to $32

B of A Securities analyst Allen Lutz maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and raises the price target from $30 to $32.

Benzinga Newsdesk

PRO
TD Cowen Maintains Hold on Hims & Hers Health, Raises Price Target to $30

TD Cowen analyst Jonna Kim maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $25 to $30.

Benzinga Newsdesk

Hims & Hers Health Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Hims & Hers Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Truist Securities Maintains Hold on Hims & Hers Health, Raises Price Target to $32

PRO
Barclays Maintains Overweight on Hims & Hers Health, Lowers Price Target to $35

PRO
Citigroup Maintains Neutral on Hims & Hers Health, Lowers Price Target to $33

PRO
Deutsche Bank Maintains Hold on Hims & Hers Health, Raises Price Target to $26

PRO
B of A Securities Maintains Neutral on Hims & Hers Health, Raises Price Target to $32

PRO
TD Cowen Maintains Hold on Hims & Hers Health, Raises Price Target to $30

People Also Watch

People Also Watch

Hims & Hers Health Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Hims & Hers Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTruist Securities Maintains Hold on Hims & Hers Health, Raises Price Target to $32

PROBarclays Maintains Overweight on Hims & Hers Health, Lowers Price Target to $35

PROCitigroup Maintains Neutral on Hims & Hers Health, Lowers Price Target to $33

PRODeutsche Bank Maintains Hold on Hims & Hers Health, Raises Price Target to $26

PROB of A Securities Maintains Neutral on Hims & Hers Health, Raises Price Target to $32

PROTD Cowen Maintains Hold on Hims & Hers Health, Raises Price Target to $30

People Also Watch

People Also Watch

PRO
Truist Securities Maintains Hold on Hims & Hers Health, Raises Price Target to $32

PRO
Barclays Maintains Overweight on Hims & Hers Health, Lowers Price Target to $35

PRO
Citigroup Maintains Neutral on Hims & Hers Health, Lowers Price Target to $33

PRO
Deutsche Bank Maintains Hold on Hims & Hers Health, Raises Price Target to $26

PRO
B of A Securities Maintains Neutral on Hims & Hers Health, Raises Price Target to $32

PRO
TD Cowen Maintains Hold on Hims & Hers Health, Raises Price Target to $30